UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

NOTICE OF EFFECTIVENESS

Effective Date:January 14,
Can Fite BioPharma (AMEX:CANF)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Can Fite BioPharma.
Can Fite BioPharma (AMEX:CANF)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Can Fite BioPharma.

Noticias sobre Can-fite Biopharma Ltd. CANF

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Lunes 15 de Abril 2024 (4 días hace) • Business Wire
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
Miércoles 3 de Abril 2024 (2 semanas hace) • Business Wire
Can-Fite Reports 2023 Financial Results and Clinical Update
Jueves 28 de Marzo 2024 (3 semanas hace) • Business Wire
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Lunes 11 de Marzo 2024 (1 mes hace) • Edgar (US Regulatory)
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Lunes 11 de Marzo 2024 (1 mes hace) • Business Wire
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Miércoles 28 de Febrero 2024 (2 meses hace) • Edgar (US Regulatory)
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
Miércoles 28 de Febrero 2024 (2 meses hace) • Business Wire
Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Miércoles 14 de Febrero 2024 (2 meses hace) • Edgar (US Regulatory)
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Martes 30 de Enero 2024 (3 meses hace) • Edgar (US Regulatory)
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
Martes 30 de Enero 2024 (3 meses hace) • Business Wire
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Lunes 29 de Enero 2024 (3 meses hace) • Edgar (US Regulatory)
Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
Lunes 29 de Enero 2024 (3 meses hace) • Business Wire

Más de Can-fite Biopharma Ltd. Artículos de Noticias